Call (844) 879-2237

Home » Conference » Dr. Matthew Regulski to Present Clinical Results of RestrataⓇ Wound Matrix at  International Wound Care Conference

Dr. Matthew Regulski to Present Clinical Results of RestrataⓇ Wound Matrix at  International Wound Care Conference

St. Louis, Missouri, June 12, 2018 – Dr. Matthew Regulski, DPM, will be giving a presentation titled “Clinical Evaluation of a Novel Nanofiber Matrix For the Treatment of Chronic Wounds” at the International Conference on Wound Care, Tissue Repair & Regenerative Medicine (Wound Care 2018) on June 14-15, 2018, in London, England.

During the presentation, Dr. Regulski will share results from a retrospective study titled “Evaluate Clinical Efficacy of Nanofiber Matrix in Treating Chronic Lower Extremity Wounds”. The study reports wound care results from 70 patients with 82 chronic wounds (34 DFUs, 34 VLUs, and 14 other chronic wounds) received treatment with Restrata Wound Matrix (Restrata). Results show that 85.0% of wounds treated with Restrata achieved complete closure at 12 weeks, with an average time to closure of 4.8 ± 3.0 weeks. The study also concluded that Restrata is effective in both VLUs and DFUs.

 

Dr. Matthew Regulski, Physician Certified in Wound Care C.M.E.T., F.A.P.W.C.A., F.C.C.W.S., W.H.S. F.A.P.W.H.©

DrRegulski works in Toms River, NJ and specializes in Podiatric Medicine. Dr. Regulski is affiliated with Ocean County Foot & Ankle Surgical Associates, P.C. For more information about DrRegulski, please visit http://www.ocfasa.com/ocean-county-foot-ankle-our-team.html

 

About International Conference on Wound Care, Tissue Repair, and Regenerative Medicine 2018 (Wound Care 2018)

Wound Care 2018, held in London, England from June 14-15, 2018 is focused on the theme of Fostering Advances in Wound Healing and Tissue Regeneration Techniques. For more information about the conference, please visit http://woundcare.alliedacademies.com/

 

About Acera

Acera is a bioscience company commercializing a portfolio of implantable nanomedical scaffolds for medical applications.  Acera’s products exhibit a structure similar to native extracellular matrix (ECM) and thus support rapid and effective healing. Acera is currently commercializing its first two products, the Cerafix® Dural Substitute and the Restrata® Wound Matrix, both FDA cleared via 510(k).

For additional information on Acera Surgical or the Restrata® Wound Matrix, please visit www.acera-surgical.com.

Comments are closed.